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Active components of complementary/alternativemedicines and natural supplements are often anionic compounds and flavonoids.
As such, organic anion transporters (OATs) may play a key role in their pharmacokinetic and pharmacological profiles, and
represent sites for adverse drug-drug interactions. Therefore, we assessed the inhibitory effects of nine natural products, including
flavonoids (catechin and epicatechin), chlorogenic acids (1,3- and 1,5-dicaffeoylquinic acid), phenolic acids (ginkgolic acids (13 : 0),
(15 : 1), and (17 : 1)), and the organic acids ursolic acid and 18𝛽-glycyrrhetinic acid, on the transport activity of the human OATs,
hOAT1 (SLC22A6), hOAT3 (SLC22A8), and hOAT4 (SLC22A11). Four compounds, 1,3- and 1,5-dicaffeoylquinic acid, ginkgolic acid
(17 : 1), and 18𝛽-glycyrrhetinic acid, significantly inhibited hOAT1-mediated transport (50 𝜇M inhibitor versus 1 𝜇Msubstrate). Five
compounds, 1,3- and 1,5-dicaffeoylquinic acid, ginkgolic acids (15 : 1) and (17 : 1), and epicatechin, significantly inhibited hOAT3
transport under similar conditions. Only catechin inhibited hOAT4. Dose-dependency studies were conducted for 1,3-dicaffeoyl-
quinic acid and 18𝛽-glycyrrhetinic acid on hOAT1, and IC
50
values were estimated as 1.2 ± 0.4 𝜇M and 2.7 ± 0.2 𝜇M, respectively.
These data suggest that 1,3-dicaffeoylquinic acid and 18𝛽-glycyrrhetinic acid may cause significant hOAT1-mediated DDIs in vivo;
potential should be considered for safety issues during use and in future drug development.
1. Introduction
In concert with our growing knowledge of drug trans-
porter expression and function, transporter-mediated drug-
drug interactions (DDIs) are being increasingly identified
by numerous in vitro and in vivo studies [1, 2]. Recently,
government agencies in the United States (Food and Drug
Administration) and Europe (European Medicines Agency),
as well as the pharmaceutical industry have acknowledged
that transporters play a key role in the absorption, distri-
bution, and excretion of many clinical therapeutics. Organic
anion transporter 1 (OAT1; SLC22A6), OAT3 (SLC22A8),
and OAT4 (SLC22A11) are among the transporters identified,
thus far, to impact the pharmacokinetics, and hence dosing,
efficacy, and toxicity, of some drugs. OAT1 and OAT3,
expressed in the basolateral membrane of renal proximal
tubule cells in both humans and preclinical species, function
as key mediators for organic solute flux from blood to
the glomerular filtrate [1, 2]. Additionally, OAT4, which
is exclusively expressed in the apical membrane of human
proximal tubules, reabsorbs anionic compounds from the
urine [1]. Further, many endogenous substances, including
hormones, neurotransmitters, and toxins, have been iden-
tified as substrates and/or inhibitors of OATs [1, 2]. Thus,
the potential clinical significance of OAT-mediated DDIs is
firmly recognized.
Although many studies have exhibited OAT-mediated
DDIs for synthesized drugs, relatively little is known about
the potential interaction between OATs and natural prod-
ucts, including various organic anions, phenolic acids, and
flavonoids found in herbal supplements and food. Several
dietary flavonoids and their metabolic conjugates (e.g., sul-
fates and glucuronides) were identified as potent inhibitors
and/or substrates of human (h) OAT1, hOAT3, and hOAT4
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[3, 4]. Phenolic acids, for example, contained in the widely
used Chinese herbal medicine Danshen (Salvia miltiorrhiza)
or common berries such as strawberries or blueberries, were
similarly demonstrated to interact with these three trans-
porters [5, 6]. These studies highlight the strong potential
for hOAT-mediated natural product-drug interaction and the
need to investigate further anionic compounds and flavo-
noids that are found in popular complementary/alternative
medicines and natural supplements.
Catechin and epicatechin are major components of tea
products, possessing antioxidative and purported anticancer
properties [7, 8]. 1,3- and 1,5-dicaffeoylquinic acids are two
enantiomers of dicaffeoylquinic acid with various pharma-
cological effects, which are widely distributed in plants (e.g.,
coffee beans, sweet potato leaves, and fennels) [9]. Indeed,
1,3-dicaffeoylquinic acid (also known as cynarin) is being
actively investigated for its anti-HIV and immunosuppressive
properties [10]. Extracts of Ginkgo biloba have gained pop-
ularity as a herbal supplement because they are believed to
improve mental sharpness and memory, while slowing brain
aging, and were hoped to be effective in relieving symptoms
associated with Alzheimer’s disease. Regardless, it is well
recognized that several ginkgolic acids, particularly (13 : 0),
(15 : 1), and (17 : 1) (designating the number of carbon atoms
in the alkyl side chain), can produce severe allergic, cytotoxic,
mutagenic, carcinogenic, and genotoxic effects [11]. Licorice
root (Radix Glycyrrhizae) is employed to relieve a number
of maladies including stomach ulcers, colic, chronic gas-
tritis, sore throat, bronchitis, osteoarthritis, liver disorders,
malaria, and tuberculosis. One major component of Radix
Glycyrrhizae preparations, glycyrrhizin, gives rise to two
bioactive metabolites, 18𝛼- and 18𝛽-glycyrrhetinic acid,
thought to play a role in these beneficial effects [12]. Ursolic
acid is a pentacyclic triterpene acid occurring naturally in
herbs and fruits. It exhibits anti-inflammatory and anticar-
cinogenic activities [13] and is marketed as a herbal sup-
plement to promote weight loss. Since these compounds
have been identified as major components of first-line/com-
plementary/alternative medicines, foods, and beverages,
humans can be exposed to these compounds through clinical
therapies and the daily diet. Many of these compounds have
shown systemic exposure in humans (Table 1). Based on
their chemical structures and previous studies, these com-
pounds have the potential to interact with OATs.Thus, OAT-
mediated DDIs may occur in vivo when combined with
known OAT substrates and such information should prove
helpful in guiding the safe use and development of products
that contain these compounds.
Therefore, the purpose of the present study was to in-
vestigate the inhibitory potential of these nine compounds,
catechin, epicatechin, 1,3- and 1,5-dicaffeoylquinic acids,
ginkgolic acids (13 : 0), (15 : 1) and (17 : 1), 18𝛽-glycyrrhetinic
acid, and ursolic acid, on hOAT1-, hOAT3- and hOAT4-
mediated transport activities. In addition to generating trans-
porter specific inhibition profiles, dose-response studies were
conducted for potent inhibitors in order to derive inhibitory
constants (IC
50
and 𝐾
𝑖
values) to aid evaluation of their
potential for clinical OAT-mediated DDIs.
2. Material and Methods
2.1. PurifiedChemicals. Catechin, 1,3- and 1,5-dicaffeoylquin-
ic acids, epicatechin, ginkgolic acids (13 : 0), (15 : 1) and (17 : 1),
and ursolic acid (all≥97% purity) were purchased fromTauto
Biotech (Shanghai, China). 18𝛽-glycyrrhetinic acid (≥97%
purity) was obtained from Sigma-Aldrich (St. Louis, MO).
The chemical structures of these compounds are shown
in Figure 1. Tritiated p-aminohippuric acid ([3H]PAH) and
estrone sulfate ([3H]ES) were purchased from PerkinElmer
Life and Analytical Sciences (Waltham, MA), and unlabeled
PAH, ES, and probenecid were purchased from Sigma-
Aldrich (St. Louis, MO).
2.2. Cell Culture. Derivation and culture of stably transfected
Chinese hamster ovary (CHO) cells expressing hOAT1
(CHO-hOAT1) and hOAT4 (CHO-hOAT4), stably trans-
fected human embryonic kidney 293 (HEK) cells expressing
hOAT3 (HEK-hOAT3), and their corresponding empty vec-
tor transfected background control cell lines, have been des-
cribed previously [6, 14–16].
2.3. Cell Accumulation Assays. The cell accumulation assay
protocol was performed as described in our recent publica-
tions with minor modifications [14, 17]. In brief, 2× 105 cells/
well were seeded in 24-well tissue culture plates and grown in
the absence of antibiotics for two days. For transport experi-
ments cells were preincubated in transport buffer without
substrates or inhibitors for 10min after which time the buffer
was replaced with 400 𝜇L of fresh transport buffer containing
1 𝜇M [3H]PAH (0.5 𝜇Ci/mL) or [3H]ES (0.25𝜇Ci/mL) with
or without test compounds. After incubation for times spec-
ified in the figure legends, cellular uptake was quenched by
quickly rinsing each well three times with fresh ice-cold
transport buffer. Cells were lysed with 1M NaOH and radio-
activity was measured with a liquid scintillation counter and
reported as picomoles of substrate per milligram total pro-
tein. All intracellular uptake data were corrected for back-
ground accumulation in corresponding empty vector trans-
fected control cells. Kinetic calculations were performed
using GraphPad Prism Software version 5.0 (GraphPad Soft-
ware Inc., San Diego, CA). The half maximal inhibitory con-
centrations (IC
50
) and inhibitory constants (𝐾
𝑖
) were calcu-
lated using nonlinear regression with the appropriatemodels.
Results were confirmed by repeating all experiments at least
three times with triplicate wells for each data point. For
kinetic analysis, hOAT1 expressing cells showed linear PAH
uptake for the initial 3min with 𝐾
𝑚
= 15.4 𝜇M [15], while
hOAT3 expressing cells exhibited linear ES uptake for the
initial 1min with𝐾
𝑚
= 14.5 𝜇M [6].
2.4. Statistics. Values are expressed as mean± S.D. or mean±
S.E.M. as indicated. Statistical differences were assessed using
one-way analysis of variance (ANOVA) followed by post hoc
analysis with Dunnett’s t-test (𝛼 = 0.05).
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Figure 1: Chemical structures of compounds investigated in this study. MW: molecular weight.
Table 1: Maximum plasma concentration (𝐶max) reported in human subjects.
Compound 𝐶max (𝜇M) Route of administration Dose (mg) Reference
Epicatechin 0.20 Oral 37 [7]
1,5-Dicaffeoylquinic acid 0.14 Oral 600 [23]
18𝛽-Glycyrrhetinic acid 0.11–2.9a Oral 130–144 (glycyrrhizin) [12, 24, 25]
Ursolic acid 7.4 i.v. 186 [13]
aAssuming plasma concentration of 18𝛼- and 18𝛽-glycyrrhetinic acid is about 1 : 3 as reported in [12].
3. Results
3.1. Inhibition of hOAT1 by Natural Anionic Compounds and
Flavonoids. Approximately threefold greater accumulation
of PAH was observed in CHO-hOAT1 cells (6.30 ±
0.97 pmolmg protein−1 10min−1) than in empty vector
transfected background control cells (2.12 ± 0.19 pmolmg
protein−1 10min−1). The hOAT1-mediated PAH accumula-
tion was almost completely inhibited by probenecid
(Figure 2). The nine test compounds, catechin, 1,3- and
1,5-dicaffeoylquinic acid, epicatechin, ginkgolic acids (13 : 0),
(15 : 1) and (17 : 1), 18𝛽-glycyrrhetinic acid, and ursolic
acid, were assessed for inhibitory effects on hOAT1-mediated
uptake (Figure 2). 1,3- and 1,5-Dicaffeoylquinic acid (64%and
22% inhibition, resp.), ginkgolic acid (17 : 1) (42% inhibition),
and 18𝛽-glycyrrhetinic acid (56% inhibition) each signifi-
cantly inhibited hOAT1-mediated PAH uptake at 50-fold
excess. Ursolic acid produced a significant stimulation of
uptake and the other compounds were without effect. Since
1,3-dicaffeoylquinic acid and 18𝛽-glycyrrhetinic acid produc-
ed inhibition greater than 50%, they were further chara-
cterized by dose-response studies (0.01–500 𝜇M, shown in
Figure 3). Estimated IC
50
values were 1.2 ± 0.4 𝜇M for 1,3-
dicaffeoylquinic acid and 2.7 ± 0.2 𝜇M for 18𝛽-glycyrrhetinic
acid. Numerous studies investigating the mode of inhibition
produced on hOAT1 and hOAT3 for a broad array of com-
pounds have demonstrated the interaction to be competitive
[5, 18–22]. Therefore, assuming competitive inhibition of
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Figure 2: Inhibitory effects of the nine test compounds on hOAT1-
mediated PAH uptake. Ten-minute uptake of [3H]PAH (1𝜇M) was
measured in CHO-hOAT1 cells in the absence and presence of
test compounds (50 𝜇M) or probenecid (1000𝜇M). Data represent
hOAT1-mediated transport specifically, that is, data have been
corrected for background PAH accumulation measured in empty
vector transfected cells. Values are mean ± S.D. of triplicate values
from a representative experiment. ∗∗ denotes 𝑃 < 0.01, and
∗∗∗ denotes 𝑃 < 0.001 as determined by one-way ANOVA followed
by Dunnett’s t-test.
hOAT1, inhibition constants (𝐾
𝑖
) were estimated as 1.1 ±
0.2 𝜇M for 1,3-dicaffeoylquinic acid and 2.5 ± 0.2 𝜇M for
18𝛽-glycyrrhetinic acid.
3.2. Inhibition of hOAT3 by Natural Anionic Compounds and
Flavonoids. Human OAT3 expressing cells showed about
4-fold greater accumulation of ES as compared to back-
ground control cells (10.6 ± 0.5 versus 2.6 ± 0.3 pmol mg
protein−1 10min−1, resp.). Similar to hOAT1, hOAT3-med-
iated ES uptake was completely (>96% inhibition) blocked by
probenecid (Figure 4). Five of the compounds, 1,3- and 1,5-
dicaffeoylquinic acid, epicatechin, and ginkgolic acids (15 : 1)
and (17 : 1), significantly inhibited hOAT3-mediated trans-
port at 50-fold excess (Figure 4). 1,3-Dicaffeoylquinic acid
and ginkgolic acid (17 : 1) exhibited 41% inhibition, while 30–
35% reduction of hOAT3-mediated ES uptake was observed
for 1,5-dicaffeoylquinic acid, epicatechin, and ginkgolic acid
(15 : 1). Catechin, 18𝛽-glycyrrhetinic acid, and ursolic acid
failed to produce significant inhibition. Based on the level of
inhibition observed, IC
50
values for all of these compounds
would be greater than 50 𝜇M, much higher than clinically
relevant concentrations (Table 1). Therefore, further dose-
response studies were not performed.
3.3. Inhibition of hOAT4 by Natural Anionic Compounds
and Flavonoids. Stably transfected hOAT4-expressing cells
showed ∼18 fold higher accumulation of ES than back-
ground control cells (42.5 ± 5.1 versus 2.4 ± 0.2 pmolmg
protein−1 10min−1, resp.).HumanOAT4-mediated ES uptake
was virtually completely blocked (>96% inhibition) by self-
inhibition (Figure 5). Catechin (50𝜇M) was the only com-
pound that showed a significant inhibitory effect (32%)
on hOAT4 (Figure 5). 1,5-Dicaffeoylquinic acid and 18𝛽-
glycyrrhetinic acid produced significant stimulation of ES
uptake. Accordingly, the IC
50
value for catechin on hOAT4
transport activity should be greater than 50 𝜇M and no fur-
ther kinetic studies were performed.
4. Discussion
Literally hundreds of therapeutic and endogenous com-
pounds have been demonstrated to interact with OATs [1, 2].
Precisely because of their broad, polyspecific nature, OATs
are likely sites for DDIs in vivo. As a consequence, they have
been identified worldwide as a family of “clinically relevant”
transporters in recent government guidances to the pharma-
ceutical industry [1, 2]. Unlike Western drugs, the pharma-
cokinetic and pharmacological properties of botanical drug
products and natural supplements have not been well inves-
tigated. Being naturally derived, people often view these com-
pounds as “safe” and without potential for causing adverse
events. However, there is increasing evidence demonstrating
potent interactions between components of natural products
and OATs, resulting in possible toxicity and DDIs [1, 2]. For
example, aristolochic acid, a potent nephrotoxic contam-
inant sometimes found in certain Chinese herbal thera-
pies, was identified as a high affinity substrate of murine
Oat1, Oat2, and Oat3, as well as a potent inhibitor of
hOAT1, hOAT3, and hOAT4 [26, 27]. Additional studies have
demonstrated the OAT-mediated DDI potential for common
flavonoid and phenolic acid components of foods and herbal
medicines [3–6]. These investigations showed that many
dietary/phytomedicine-derived organic acids and flavonoids
have a high inhibitory potency for hOAT1, hOAT3, and/or
hOAT4 and, according to proposed guidelines established by
the FDA and EMA, high likelihood to result in significant
DDIs in vivo [1–6]. Therefore, further studies on OAT-med-
iated natural product-drug interactions are needed in order
to establish informed safety and efficacy profiles for botanical
products.
In the present study, we characterized the interactions of
nine chemically diverse compounds including flavonoids,
chlorogenic acids, phenolic acids, and other organic acids,
found as major dietary or phytomedicine components, with
three human OATs: hOAT1, hOAT3, and hOAT4. As illus-
trated, most of the compounds produced significant inhibi-
tion of hOAT1 and hOAT3 at a 50-fold excess concentration
(Figures 1 and 3). In marked contrast, only catechin signif-
icantly inhibited hOAT4 under this condition (Figure 5).
Interestingly, ursolic acid caused a significant stimulation of
hOAT1-mediated PAH uptake while it was without effect on
either hOAT3 or hOAT4 transport activity. Similarly, 1,5-di-
caffeoylquinic acid and 18𝛽-glycyrrhetinic acid appeared to
significantly stimulate hOAT4 transport while decreasing
hOAT1- and hOAT3-mediated uptake activities. Such spo-
radic transporter stimulation/inhibition has been previously
reported in the literature for other compounds. For example,
for fluoroquinolone antimicrobials, ciprofloxacin inhibited
hOAT3, but stimulated hOAT1 [14], and sparfloxacin was
reported to stimulatemultidrug resistance-associated protein
2 activity [28]. Such stimulation of transport activity in vitro
also has been reported for steroids, chemotherapeutic agents,
and nonsteroidal anti-inflammatory drugs [14, 28–30]. One
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Figure 3: Dose-response effects for 1,3-dicaffeoylquinic acid and 18𝛽-glycyrrhetinic acid on hOAT1-mediated PAH transport. One-minute
uptake of [3H]PAH (1 𝜇M) in CHO-hOAT1 cells was measured in the presence of increasing concentrations (10−7 to 5 × 10−4 M) of test
compounds. Data were corrected by subtracting background PAH accumulation measured in empty vector transfected cells. IC
50
values
were determined with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad Prism software. Experiments
were repeated three times with triplicate samples and graphs shown are from representative experiments with values plotted as mean ± S.D.
(𝑛 = 3). The data were used to generate mean IC
50
± S.E.M. estimates.
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Figure 4: Inhibitory effects of the nine test compounds on hOAT3-
mediated ES uptake. Ten-minute uptake of [3H]ES (1𝜇M) was
measured in HEK-hOAT3 cells in the absence and presence of
test compounds (50 𝜇M) or probenecid (1000𝜇M). Data represent
hOAT3-mediated transport specifically, that is, data have been cor-
rected for background ES accumulation measured in empty vector
transfected cells. Values are mean ± S.D. of triplicate values from a
representative experiment. ∗ denotes 𝑃 < 0.05, ∗∗ denotes 𝑃 < 0.01,
and ∗∗∗ denotes 𝑝 < 0.001 as determined by one-way ANOVA
followed by Dunnett’s t-test.
potential explanation is allosteric binding of the compounds
to the transporters with subsequent alteration of substrate
affinity [28, 29]. However, these transporters share a high
degree of sequence identity, and no readily discernible struc-
tural differences corresponding to such a binding site are
apparent, and these effects do not exhibit a consistent pattern
among the hOATs. Whether these effects will be observed in
vivo is yet to be determined; however, in such an instance
increased (versus decreased) elimination and shortened (ver-
sus lengthened) terminal half-life of victim drugs could occur
causing loss of efficacy.
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Figure 5: Inhibitory effects of the nine test compounds on hOAT4-
mediated ES uptake. Ten minute uptake of [3H]ES (1 𝜇M) was
measured in CHO-hOAT4 cells in the absence and presence of
test compounds (50 𝜇M) or ES (1000𝜇M for self-inhibition). Data
represent hOAT4-mediated transport specifically, that is, data have
been corrected for background ES accumulation measured in
empty vector transfected cells. Values are mean ± S.D. of triplicate
values from a representative experiment. ∗ denotes 𝑃 < 0.05, and
∗∗∗ denotes 𝑃 < 0.001 as determined by one-way ANOVA followed
by Dunnett’s t-test.
The FDA guidance on drug interaction studies proposed
using the DDI index, calculated as the ratio of unbound
𝐶max over IC50 or 𝐾𝑖, as an indicator of the assessment of
a compound’s DDI potential, with a value greater than 0.1
indicating the potential need to perform an in vivo DDI
study for an investigational drug. In the current study, 18𝛽-
glycyrrhetinic acid exhibited strong inhibition of hOAT1with
an estimated IC
50
of 2.7 ± 0.2 𝜇M or 𝐾
𝑖
of 2.5 ± 0.2 𝜇M
(Figures 1 and 2). Human exposure studies reported 𝐶max
values ranging from 0.11 to 2.9 𝜇M (Table 1), perhaps due to
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interindividual variability, different doses, and/or dosing reg-
imen (single dose versus repeated dose). As such, the maxi-
mum DDI for 18𝛽-glycyrrhetinic acid is ∼1.1, although this
value does not account for plasma protein binding as this is
unknown. However, if we assume it to be highly plasma pro-
tein bound, for example, 90%, the DDI index would be 0.12,
meeting the FDA guidance threshold of 0.1. Therefore, 18𝛽-
glycyrrhetinic acid may affect hOAT1-mediated renal elimi-
nation of coadministered therapeutics that are hOAT1 sub-
strates.
1,3-Dicaffeoylquinic acid is a major component found in
artichoke and Echinacea purpurea [31, 32]. Pharmacological
studies demonstrated that it exhibits antimicrobial and anti-
oxidant activity [31, 33]. Moreover, it has garnered increased
interest because of its anti-HIV and immunosuppressive pro-
perties. 1,3-Dicaffeoylquinic acid blocked HIV-1 integrase
activity, leading to interference of insertion of viral DNA into
the genome of the victim cell [10]. Another study demon-
strated that it inhibited the interaction between CD28 of T-
cell receptor and CD80 of antigen presenting cells, blocking
“signal 2” of T-cell activation [32]. Due to its potential devel-
opment as a therapeutic agent, systemic exposure in clinical
applications may reach high levels. In the present study, 1,3-
dicaffeoylquinic acid showed high affinity with hOAT1
(IC
50
=1.2 ± 0.4 𝜇M; 𝐾
𝑖
=1.1 ± 0.2 𝜇M). Therefore, the dose-
systemic exposure relationship and plasma protein binding
should be elucidated as part of the future drug development
process for this compound.
It has been reported that flavonoids can interact with
OATs [3]. Therefore, catechin and epicatechin, two flavonoid
components from green tea, were investigated for potential
interaction with hOAT1, hOAT3, and hOAT4. Both com-
pounds exhibited significant inhibition of hOAT4 and
hOAT3 when present at a 50-fold excess; however no inhibi-
tion was observed for hOAT1. Because of low reported clin-
ical plasma concentrations (Table 1), these flavonoids were
determined to be unlikely to cause DDIs after normal con-
sumption of tea products. However, OATs might promote
entry of these antioxidants into renal proximal tubules, pro-
viding a nephroprotective effect.
In summary, we investigated the potential interaction of
nine flavonoids, phenolic acids, chlorogenic acids, and other
organic acids with hOAT1, hOAT3, and hOAT4. Among the
examined compounds, 1,3-dicaffeoylquinic acid and 18𝛽-gly-
cyrrhetinic acid showed marked affinity with hOAT1. In
humans, systemic exposure of 18𝛽-glycyrrhetinic acid may
induce significant hOAT1-associated DDIs. Future in vivo
interaction studies between 18𝛽-glycyrrhetinic acid or 1,3-
dicaffeoylquinic acid and clinical therapeutics known to be
hOAT1 substrates may be necessary to establish safety guide-
lines for use of pharmaceutical products containing these
compounds to avoid potential DDIs.
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